Table 2.
Antifungal susceptibility of Candida bloodstream isolates in patients during the study period
| |
Fluconazole |
Itraconazole |
Ketoconazole |
Voriconazole |
||||
|---|---|---|---|---|---|---|---|---|
| Species | No. of isolates tested | %S# | No. of isolates tested | %S | No. of isolates tested | %S | No. of isolates tested | %S |
|
C. albicans |
31 |
23 (74.2) |
31 |
29 (93.6) |
6 |
3 (50.0) |
22 |
22 (100.0) |
|
C. parapsilosis |
26 |
15 (57.7) |
26 |
25 (96.2) |
2 |
1 (50.0) |
22 |
22 (100.0) |
|
C. glabrata |
11 |
1 (9.1) |
11 |
1 (9.1) |
1 |
0 (0) |
5 |
5 (100.0) |
|
C. tropicalis |
38 |
12 (31.6) |
38 |
25 (65.8) |
5 |
0 (0) |
23 |
21 (91.3) |
|
C. krusei |
3 |
0 (0) |
3 |
1 (33.3) |
1 |
0 (0) |
3 |
3 (100.0) |
|
C. guilliermondii |
6 |
4 (66.7) |
6 |
5 (83.3) |
0 |
0 (0) |
5 |
5 (100.0) |
| Other* |
16 |
4 (25.0) |
16 |
5 (31.3) |
3 |
3 (100.0) |
12 |
12 (100.0) |
| Total | 128 | 59 (46.1) | 131 | 91 (69.5)* | 18 | 7 (38.9) | 92 | 90 (97.8) |
*; Others include: C. pelliculosa, C. famata and C. haemuloni.
#; Abbreviations: S susceptible.